• 1. School of Medicine, University of Electronic Science and Technology of China, Chengdu 610054, P. R. China;
  • 2. Department of Hepatobiliary and Pancreatic Surgery, Liver Transplantation Center, Affiliated Cancer Hospital of University of Electronic Science and Technology, Sichuan Cancer Hospital, Chengdu 610042, P. R. China;
HUANG Xiaolun, Email: huangxiaolun@med.uestc.edu.cn
Export PDF Favorites Scan Get Citation

Objective  To summarize advances in the application of machine learning in the diagnosis and treatment of liver disease. Method  The recent literatures on the progress of machine learning in the diagnosis, treatment and prognosis of liver diseases were reviewed. Results  Machine learning could be used to diagnose and categorize substantial liver lesions, tumourous lesions and rare liver diseases at an early stage, which could facilitate clinicians to take timely and appropriate treatment measures. Machine learning was helpful in informing clinicians in choosing the best treatment decision, which was conducive to reducing medical risks. It could also help to determine the prognosis of patients in a comprehensive manner, and provide assistance in formulating early rehabilitation treatment plans, adjusting follow-up strategies and improving future prognosis. Conclusions  Multiple types of machine learning algorithms have achieved positive results in the clinical application of liver diseases by constructing different prediction models, and have great potential and excellent prospects in multiple aspects such as diagnosis, treatment and prognosis of liver diseases.

Citation: DAI Zonglin, LIANG Yuxin, LIU Yilong, HUANG Xiaolun. Advances in machine learning in treatment and diagnosis of liver disease. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2023, 30(6): 764-768. doi: 10.7507/1007-9424.202302008 Copy

  • Previous Article

    Research progress on the transition from pediatric liver transplant recipients to adult stage medical care
  • Next Article

    Interpretations of the NCCN guidelines for breast cancer risk reduction (version 2023)